153 related articles for article (PubMed ID: 34241753)
1. Predictors of Virological Suppression After Clinical Relapse in Patients Who Discontinued Entecavir or Tenofovir.
Fang HW; Yen YH; Hung CH; Wang JH; Hu TH; Lu SN; Chen CH
Dig Dis Sci; 2022 Jul; 67(7):3402-3411. PubMed ID: 34241753
[TBL] [Abstract][Full Text] [Related]
2. Higher rate of HBsAg loss after discontinuation of tenofovir than entecavir in patients with chronic hepatitis B.
Chen CH; Peng CY; Hu TH; Wang JH; Hung CH; Lu SN
Aliment Pharmacol Ther; 2023 Aug; 58(3):334-345. PubMed ID: 37265196
[TBL] [Abstract][Full Text] [Related]
3. Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy.
Kuo MT; Tseng PL; Chou YP; Chang KC; Tsai MC; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
J Gastroenterol Hepatol; 2018 Oct; 33(10):1766-1772. PubMed ID: 29514418
[TBL] [Abstract][Full Text] [Related]
4. Kinetics in HBsAg after Stopping Entecavir or Tenofovir in Patients with Virological Relapse but Not Clinical Relapse.
Tseng TN; Kuo YH; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Viruses; 2022 May; 14(6):. PubMed ID: 35746660
[TBL] [Abstract][Full Text] [Related]
5. DARING-B: discontinuation of effective entecavir or tenofovir disoproxil fumarate long-term therapy before HBsAg loss in non-cirrhotic HBeAg-negative chronic hepatitis B.
Papatheodoridis GV; Rigopoulou EI; Papatheodoridi M; Zachou K; Xourafas V; Gatselis N; Hadziyannis E; Vlachogiannakos J; Manolakopoulos S; Dalekos GN
Antivir Ther; 2018; 23(8):677-685. PubMed ID: 30044765
[TBL] [Abstract][Full Text] [Related]
6. Retreatment Efficacy and Renal Safety of Tenofovir Alafenamide, Entecavir, and Tenofovir Disoproxil Fumarate After Entecavir or Tenofovir Cessation.
Chiu SM; Chang KC; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
Dig Dis Sci; 2023 Feb; 68(2):665-675. PubMed ID: 35976597
[TBL] [Abstract][Full Text] [Related]
7. Combined baseline HBcrAg and end-of-treatment HBsAg predict HBV relapse after entecavir or tenofovir cessation.
Tseng TN; Jeng WJ; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
J Antimicrob Chemother; 2023 Feb; 78(2):436-439. PubMed ID: 36478233
[TBL] [Abstract][Full Text] [Related]
8. Associations of HBV Genotype B vs C Infection With Relapse After Cessation of Entecavir or Tenofovir Therapy.
Chiu SM; Kuo YH; Wang JH; Hung CH; Hu TH; Lu SN; Chen CH
Clin Gastroenterol Hepatol; 2020 Dec; 18(13):2989-2997.e3. PubMed ID: 32353534
[TBL] [Abstract][Full Text] [Related]
9. Combining end-of-treatment HBsAg and baseline hepatitis B core-related antigen reduce HBV relapse rate after tenofovir cessation.
Kuo YH; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
Hepatol Int; 2021 Apr; 15(2):301-309. PubMed ID: 33665773
[TBL] [Abstract][Full Text] [Related]
10. Differential Relapse Patterns After Discontinuation of Entecavir vs Tenofovir Disoproxil Fumarate in Chronic Hepatitis B.
Choi HSJ; Hirode G; Chen CH; Su TH; Seto WK; Van Hees S; Papatheodoridi M; Lens S; Wong GLH; Brakenhoff SM; Chien RN; Feld JJ; Sonneveld MJ; Chan HLY; Forns X; Papatheodoridis GV; Vanwolleghem T; Yuen MF; Hsu YC; Kao JH; Cornberg M; Hansen BE; Jeng WJ; Janssen HLA;
Clin Gastroenterol Hepatol; 2023 Jun; 21(6):1513-1522.e4. PubMed ID: 35863683
[TBL] [Abstract][Full Text] [Related]
11. Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy.
Fang HW; Tseng PL; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Virol J; 2024 Apr; 21(1):79. PubMed ID: 38570803
[TBL] [Abstract][Full Text] [Related]
12. Post-treatment HBsAg decline predicts high rate of HBsAg loss after stopping entecavir or tenofovir in HBeAg-negative patients without retreatment.
Fang HW; Hu TH; Wang JH; Hung CH; Lu SN; Chen CH
Dig Liver Dis; 2023 Sep; 55(9):1223-1229. PubMed ID: 36870864
[TBL] [Abstract][Full Text] [Related]
13. Incidence and Factors Associated With HBV Relapse After Cessation of Entecavir or Tenofovir in Patients With HBsAg Below 100 IU/mL.
Tseng TN; Hu TH; Wang JH; Kuo YH; Hung CH; Lu SN; Jeng WJ; Chen CH
Clin Gastroenterol Hepatol; 2020 Nov; 18(12):2803-2812.e2. PubMed ID: 32360818
[TBL] [Abstract][Full Text] [Related]
14. The incidence and predictors of HBV relapse after cessation of tenofovir therapy in chronic hepatitis B patients.
Chen CH; Hsu YC; Lu SN; Hung CH; Wang JH; Lee CM; Hu TH
J Viral Hepat; 2018 May; 25(5):590-597. PubMed ID: 29274189
[TBL] [Abstract][Full Text] [Related]
15. The role of hepatitis B virus core-related antigen in predicting hepatitis B virus relapse after cessation of entecavir in hepatitis B e antigen-negative patients.
Huang PY; Wang JH; Hung CH; Lu SN; Hu TH; Chen CH
J Viral Hepat; 2021 Aug; 28(8):1141-1149. PubMed ID: 33932245
[TBL] [Abstract][Full Text] [Related]
16. Comparison of HBsAg changes between HBeAg-negative patients who discontinued or maintained entecavir therapy.
Chen CH; Hu TH; Wang JH; Lai HC; Hung CH; Lu SN; Peng CY
Hepatol Int; 2020 May; 14(3):317-325. PubMed ID: 31650509
[TBL] [Abstract][Full Text] [Related]
17. Serum cytokine profiles predict outcomes of chronic hepatitis B patients discontinuing entecavir or tenofovir therapy.
Lin MJ; Su TH; Liu CJ; Yang HC; Chen CL; Liou JM; Tseng TC; Liu CH; Hong CM; Chen PJ; Kao JH
J Formos Med Assoc; 2023 Jul; 122(7):564-573. PubMed ID: 36872131
[TBL] [Abstract][Full Text] [Related]
18. Incidence and predictors of retreatment in chronic hepatitis B patients after discontinuation of entecavir or tenofovir treatment.
Ma TL; Hu TH; Hung CH; Wang JH; Lu SN; Chen CH
PLoS One; 2019; 14(10):e0222221. PubMed ID: 31584951
[TBL] [Abstract][Full Text] [Related]
19. Hepatitis B surface antigen titer is a good indicator of durable viral response after entecavir off-treatment for chronic hepatitis B.
Lee HA; Seo YS; Park SW; Park SJ; Kim TH; Suh SJ; Jung YK; Kim JH; An H; Yim HJ; Yeon JE; Byun KS; Um SH
Clin Mol Hepatol; 2016 Sep; 22(3):382-389. PubMed ID: 27729633
[TBL] [Abstract][Full Text] [Related]
20. Distinct Relapse Rates and Risk Predictors After Discontinuing Tenofovir and Entecavir Therapy.
Su TH; Yang HC; Tseng TC; Liou JM; Liu CH; Chen CL; Chen PJ; Chen DS; Liu CJ; Kao JH
J Infect Dis; 2018 Mar; 217(8):1193-1201. PubMed ID: 29300980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
